Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Description

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

Conditions

Blood Cancer, Leukemia

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Condition
Blood Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 or older
  • * English speaking
  • * Ability to understand and willingness to provide oral consent
  • * DFCI patient who are in remission from a blood cancer \>1 year will be preferred.
  • * Adults unable to consent
  • * Individuals who are not yet adults (infants, children, teenagers \<18 years old)
  • * Prisoners.
  • * Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1
  • * Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.
  • * Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Dana-Farber Cancer Institute,

Andrew Hantel, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

2028-01-01